Implications of Sarcopenia in Major Surgery by Friedman, Jeffrey et al.
Nutrition in Clinical Practice
Volume 30 Number 2 
April 2015 175 –179
© 2015 American Society
for Parenteral and Enteral Nutrition
DOI: 10.1177/0884533615569888
ncp.sagepub.com
hosted at  
online.sagepub.com
Invited Review
Understanding patient risk factors for surgical complications 
and mortality allows patients, families, and clinicians to titrate 
the intensity of optimal care. Clinicians use several methods of 
risk assessment as they recommend a treatment plan. Most 
often, they identify risk using a subjective assessment of each 
patient’s vigor and physiologic reserve.1,2 Developing tech-
niques to objectively measure the same characteristics that form 
the gestalt of the “eyeball test” may provide improved means of 
risk stratification that can be more easily communicated to 
patients.2 Understanding the patient factors and physiologic 
mechanisms underlying high-risk patients will elucidate targets 
to manage remediable risk and improve outcomes. The purpose 
of this article is to define sarcopenia, its clinical measurement 
using computed tomography (CT) scans, and the implication of 
those measurements in predicting surgical and mortality risk. 
We conclude this article with a brief discussion of proposed 
clinical implementation of risk factor remediation.
Defining Sarcopenia and Its Clinical 
Relevance
Sarcopenia, defined as the loss of skeletal muscle mass and 
strength, is associated with frailty, mortality, and poor out-
comes in both surgical and nonsurgical patients.1,3–10 Patients 
with sarcopenia are particularly vulnerable in the setting of 
major physiologic stressors such as major surgery or surgical 
complications. The development of sarcopenia is multimodal; 
factors include malnutrition, functional status, and comorbid 
disease such as cancer, age, and heredity. Progressive resis-
tance training and nutrition modifications are well-established 
interventions to reverse sarcopenia.3 Systematically identify-
ing sarcopenic patients prior to major surgery and intervening 
on their potentially remediable risk factors may be a novel tar-
get for surgical quality improvement.
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Abstract
Background: Sarcopenia, defined as a decrease in skeletal muscle mass and strength, is an important risk factor in clinical medicine 
associated with frailty, mortality, and worse surgical and nonsurgical outcomes. Conventional measures of sarcopenia rely on the subjective 
“eyeball test” and do not adequately describe risk. Computed tomography (CT) imaging studies may be used to objectively measure 
sarcopenia and may be used for surgical risk stratification and identification of patients for inclusion in a novel clinical remediation 
program. Methods: We describe results observed in the general, vascular, and liver transplant surgery populations determined by analytic 
morphomics—an analysis of CT scans in a semiautomated process using MATLAB v13.0. A perioperative optimization program has 
been implemented with the objective of remediating sarcopenia through improvement of patient mental and physical status prior to 
surgery. Results: Using analytic morphomics, we have noted significantly higher cost and increased rates of mortality and surgical 
complications among sarcopenic patients. The training program shows initial success, and among participating patients, we have observed 
reductions in payer and hospital costs and a decrease in length of hospital stay for patients following surgery. Conclusions: Through 
analytic morphomics, we are able to quantify markers of sarcopenia and identify patients at risk for increased mortality and poor surgical 
outcomes. Early identification of patients offers us the opportunity to remediate sarcopenia through perioperative training and support. 
Participating patients spend less time in the hospital and have lower healthcare costs. This program has the potential to improve the 
perioperative patient experience and ease financial burdens. (Nutr Clin Pract. 2015;30:175-179)
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Using Preoperative Imaging for Risk 
Assessment
Prior to major surgery, patients undergo an extensive radio-
graphic workup. These images determine suitability for sur-
gery and allow the surgeon to formulate an operative plan. 
Surgeons evaluate the areas of pathology, while the rest of the 
patient’s body is not assessed. Radiographic imaging offers an 
untapped resource for risk stratification. Quantified global 
assessments of patient health and risk can be determined from 
these same preoperative imaging studies.2,4,6,7,9–11 An example 
can be seen in Figure 1, which displays cross-sectional CT 
images taken at the level of the fourth lumbar vertebrae of two 
58-year-old male patients with a history of diabetes, chronic 
obstructive pulmonary disease (COPD), and myocardial 
infarction who are preparing for elective sigmoid colectomy. 
By conventional risk stratification and the “eyeball test,” these 
patients may look similar.2 However, important differences are 
demarcated through quantified body composition measure-
ments calculated using preoperative CT imaging studies, a pro-
cess called analytic morphomics.
Investigating the Utility of Analytic 
Morphomics
Beyond the obvious visual disparity observed in patient 
scans, quantitative measures of body composition can be 
made to determine objective measures of surgical risk. 
Analytic morphomic processing is completed on CT images 
in a semiautomated manner using algorithms programmed in 
MATLAB v13.0 (MathWorks, Natick, MA). Our work notes 
that sarcopenia within the trunk muscles is a dominant risk 
factor for poor outcomes. The psoas muscles, the paraspinous 
muscles, and the thigh muscles offer reliable measures of 
sarcopenia in CT cross-sectional imaging.2,4,6,7,11 As shown in 
Figure 2, an examination of the psoas muscles at the fourth 
lumbar vertebrae in major, elective general and vascular 
surgery patients revealed that trunk muscle area is normally 
distributed, and extremes of the population are notably differ-
ent. Examination of the upper and lower tertiles of core muscle 
size (controlling for relevant patient risk factors and opera-
tive case complexity) shows 1-year survival to be 95% vs 
87% and 3-year survival to be 91% vs 75%, respectively.9 
Among patients with chronic liver disease undergoing liver 
transplantation, the association of core muscle size with 
survival is even more dramatic. Upper quartile patients expe-
rience 87% one-year survival and 77% three-year survival vs 
50% and 26% survival, respectively, among lower quartile 
patients.4 Importantly, core muscle size is the strongest 
predictor of survival. In addition to mortality, sarcopenia is 
associated with surgical complications.12 Among general and 
vascular surgery patients, average risk of complication is 
12%, 15%, and 21%, respectively for the upper, middle, and 
lower tertiles of core muscle size.9
Other morphomic measures of body composition, such as 
subcutaneous fat, correlate with surgical outcomes. Among 
Figure 1. Computed tomography scan comparison showing body composition differences between a sarcopenic (left) and 
nonsarcopenic (right) patient. Note the smaller and less clearly defined muscle groups adjacent to the vertebra of the sarcopenic patient 
compared with the robust and clearly defined muscle groups of the nonsarcopenic patient. COPD, chronic obstructive pulmonary 
disease. Adapted with permission from Englesbe MJ, Lee JS, He K, et al. Analytic morphomics, core muscle size, and surgical 
outcomes. Ann Surg. 2012;256(2):255-261.
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patients undergoing a midline laparotomy, increased subcuta-
neous fat is a predictor of superficial, incisional surgical site 
infection (SSI).10 Figure 3 displays rate of SSI by quartile of 
body mass index (BMI) and subcutaneous fat after adjusting 
for other independent predictors, including tobacco use, ste-
roids, American Society of Anesthesiologists (ASA) risk class, 
and operative time. Importantly, subcutaneous fat measure-
ment better discriminates risk compared with BMI.
Patients with sarcopenia are significantly more expensive to 
care for. For patients undergoing major general or vascular sur-
gery, decreasing lean core muscle size is associated with 
increasing costs for insurers. Sarcopenic patients had a mean 
payer cost of $34,796, while nonsarcopenic patients had a 
mean payer cost of $21,380.6 Figure 4 displays this relation-
ship by percentile of lean psoas area and payer costs for major 
elective abdominal surgery.
Figure 2. Distribution of lean psoas muscle area in males and females. Adapted with permission from Englesbe MJ, Lee JS, He K,  
et al. Analytic morphomics, core muscle size, and surgical outcomes. Ann Surg. 2012;256(2):255-261.
Figure 3. Comparison of surgical site infection rates by body mass index (BMI) and subcutaneous fat measurement.
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Sarcopenia: What Can Be Done Prior to 
Surgery?
Understanding the financial implications of sarcopenia is 
critical to drive change. Interventions such as preoperative 
physical training and nutrition intervention are expensive. 
Furthermore, the costs of these interventions are not easily 
recoverable, since they lie outside of the surgical episode pay-
ments. Most clinicians are easily convinced that presurgical 
interventions focused on sarcopenic and malnourished patients 
are good for patient care, making developing programs that are 
financially viable a must.
Investment in programs to optimize patients prior to 
surgery is good business for hospitals and payers. Of course, 
giving the best care possible is a priority for all stakeholders, 
and patient satisfaction is good for business. Beyond this, tar-
geted preoperative interventions save money. This is rooted in 
the observations detailed above; sarcopenic patients are high 
risk and expensive.
Exercise training can rapidly and significantly improve 
functional health, especially in deconditioned individuals.13–16 
Preoperative exercise may improve surgical outcomes and is 
feasible, although it has not been accepted as standard of care 
and is not normal clinical practice.17–20 Nutrition assessment 
and intervention are also key components of these interventions 
and must be done efficiently so as not to add unnecessary costs.
Implementing a Program for Remediation 
of Perioperative Risk
Motivated by our work in sarcopenia, we began studying and 
implementing perioperative optimization as the standard of 
care for all patients. Much as an athlete trains for competition, 
patients should train for surgery by reducing remediable risk, 
including sarcopenia. The Michigan Surgical Home & 
Optimization Program (MSHOP) is a preoperative training 
program that includes physical exercise, cessation of smoking, 
stress reduction, nutrition support, and daily spirometer 
exercises that is being implemented at the University of 
Michigan. More than 350 patients have been enrolled in the 
pilot program.
The primary outcomes for this clinical program have been 
related to the patient-centered experience and financial data. 
Feedback from families and patients has been uniformly positive. 
Patients feel engaged with the perioperative care process and in 
control of their outcomes. To assess the financial outcomes of the 
program, we matched participating patients to historical controls 
based on age, sex, ASA risk class, case complexity, and Medicare 
Allowable Payments using standard propensity matching tech-
niques. The preliminary results note a consistent reduction in 
costs for the payer and hospital of and a 2-day reduction in length 
of stay in the hospital following surgery.
The genesis of MSHOP was the observation that patients 
with small muscles on preoperative imaging do poorly with 
major surgery. Early trials focused on muscle strength inter-
ventions. It soon became clear that the severity of illness and 
complexity of the patient’s nutrition status made rigorous 
assessments of sarcopenia interventions challenging. We 
eventually moved toward a commonsense clinical program, 
focusing on a broad range of interventions. Which interven-
tions are most effective is not yet known, but all are low cost 
with the exception of aggressive nutrition modifications for 
malnourished patients. Most important, MSHOP has facili-
tated a cultural change. Our expectation is that all patients 
train for elective surgery. In our experience, most patients 
embrace this opportunity. The program empowers patients 
Figure 4. Mean adjusted payer cost for major general elective surgery by lean psoas area. Costs describe expenses incurred over the 
period of 3 days prior to surgery through postoperative discharge.
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during a time of great fear and uncertainty. As we use novel 
techniques such as CT scans to assess patient-specific risk 
factors for poor outcomes, clinical programs to mitigate 
remediable risk will become tailored for each patient.
Conclusion
Use of analytic morphomics can aid in patient risk stratification. 
Identifying sarcopenic patients and correcting their remediable 
risk factors prior to surgery is of the utmost importance since this 
patient cohort has worse surgical outcomes, increased mortality 
rates, and higher total payer costs compared with patients without 
sarcopenia. We recommend the use of a preoperative training 
program for patients with remediable perioperative risk factors to 
help improve outcomes, lower costs, and decrease length of stay.
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